Objective To develop the Chinese version of Patient Learning Needs Scale(PLNS), and evaluate the feasibility, validity and reliability of the developed scale. Methods The standard procedure of cross-culture adaptation was used to develop the Chinese version PLNS. A total of 385 adults hospitalized with a medical or surgical illness completed the Chinese version PLNS. The feasibil-ity and psychometric properties of the scale such as, internal consistency, split-half reliability, content validity and construct validity were evaluated. Results Questionnaire recovery rate of the investiga-tion was 98.5%,the completion rate was 97.7%. Average time of completing was (13.75±4.36) min. The overall Cronbaeh's α coefficient was 0.95 and the value of a in 5 subscales of PLNS ranged from 0.75 to 0.86. The overall split-half reliability coefficient was 0.95 and the value of split-half in 5 subscales of PLNS ranged from 0.802 to 0.876. The CVI for content validity was 0.86. The construct validity was con-finned by factor analysis with 55,08% variance was explained by 9 factors. Conclusions An accept-able psychometric property of the Chinese version of PLNS was indicated. PLNS could be used as positive aspects measurement of general patients'perceptions of learning needs while discharging.It might be help-ful for care and further clinical study.

Objective To analyze the antibiotic resistance of ureaplasma urealyticum(UU) in vitro in Yangjiang,and instruct the clinical treatment for the ureaplasma urealyticum infection.Methods 538 secretion samples of urethra and cervix were collected and cultured ureaplasma urealyticum in vitro,the drug sensitive test of UU from 253 patients was conducted and detected their drug resistance.Results The 253 positives cases were found in 538 samples.The drug sensitive test results were:the highest sensitivity rates were clarithromycin(731%) and roxithromycin(679%).The resistance rates of rest drugs were azithromycin(771%),josamycin(708%),minocycline(664%),ciprofloxacin(538%),sparfloxacin(435%),doxycycline(423%),the total resistance rate was 489%.Conclusion To treat the ureaplasma urealyticum infection,the first choices are clarithromycin and roxithromycin.

Objective:To observe the clinical efficacy of Qingzhenfang for plasmoby （chronic urticaria）， and to investigate its effect on cellular immune function. Method:One hundred and thirty-two cases patients were divided into control group and observation group evenly according to random number table. The 60 patients in control group finished the study because of 6 cases of dropout， loss of follow-up and withdrawal， and 62 patients in observation group finished the study. Patients in both groups got Yiebastine tablets， 10-20 mg/time， 1 time/day. Patients in control group additionally got Piminxiao capsule， 4 grains/time， 3 times/day， while patients in observation additionally got Qingzhenfang， 1 dose/day. The treatment continued for 8 weeks in both groups. Before the treatment， and at the second， fourth， and eighth week after treatment， scores of urticaria activity for 7 days （USA7） and total symptom score （TSS） were graded. Before and after treatment， scores of chronic urticaria quality of life scale （CU-Q2oL） and syndrome of rheumatic fever were graded. A follow-up of 3 months was conducted for the patients whose score of USA7 was less than 7 to record the recurrence. Complement 3 and 4 （C3， C4）， CD4⁺， CD8⁺ cells were detected， and Th17/ CD4⁺ and Treg/ CD4⁺， CD4⁺/CD8⁺ and Th17/Treg were calculated. Levels of peripheral blood interleukin-10 （IL-10）， IL-17 and IL-23 were detected， and safety was evaluated after the treatment. Result:At the second， fourth and eighth week after the treatment， scores of USA7， TSS， CU-Q2oL and syndrome of rheumatic fever in observation group were lower than those in the control group （P<0.01）. Levels of C3， C4， CD4⁺， Treg， CD4⁺/CD8⁺and IL-35 in observation group were higher than those levels detected in control group （P<0.01）， while levels of CD8⁺， Th17， Th17/Treg， IL-10， IL-17 and IL-23 were lower than those in the control group （P<0.01）. Recurrence rate was 25.58% （11/43） in observation group， lower than 48.48% （16/33） in control group （χ2=4.276， P<0.05）， and the clinical efficacy in observation group was superior to that in control group （Z=2.021， P<0.05）. Conclusion:Yaoyi Qingzhenfang can control the degree of disease and improve the quality of life for patients with chronic urticaria， with superior clinical efficacy. In addition， it can reduce recurrence rate， increase the levels of C3， C4， regulate cellular immune function， and reduce immune inflammatory response， so it is worthy of further clinical research and use.

Cordycepin exerts neuroprotective effects against excitotoxic neuronal death. However, its direct electrophysiological evidence in Alzheimer's disease (AD) remains unclear. This study aimed to explore the electrophysiological mechanisms underlying the protective effect of cordycepin against the excitotoxic neuronal insult in AD using whole-cell patch clamp techniques. β-Amyloid (Aβ) and ibotenic acid (IBO)-induced injury model in cultured hippocampal neurons was used for the purpose. The results revealed that cordycepin significantly delayed Aβ + IBO-induced excessive neuronal membrane depolarization. It increased the onset time/latency, extended the duration, and reduced the slope in both slow and rapid depolarization. Additionally, cordycepin reversed the neuronal hyperactivity in Aβ + IBO-induced evoked action potential (AP) firing, including increase in repetitive firing frequency, shortening of evoked AP latency, decrease in the amplitude of fast afterhyperpolarization, and increase in membrane depolarization. Further, the suppressive effect of cordycepin against Aβ + IBO-induced excessive neuronal membrane depolarization and neuronal hyperactivity was blocked by DPCPX (8-cyclopentyl-1,3-dipropylxanthine, an adenosine A₁ receptor-specific blocker). Collectively, these results revealed the suppressive effect of cordycepin against the Aβ + IBO-induced excitotoxic neuronal insult by attenuating excessive neuronal activity and membrane depolarization, and the mechanism through the activation of A₁R is strongly recommended, thus highlighting the therapeutic potential of cordycepin in AD.
Action Potentials ; Adenosine ; Alzheimer Disease ; Fires ; Ibotenic Acid ; Membranes ; Neurons ; Neuroprotection ; Neuroprotective Agents ; Patch-Clamp Techniques ; Pyramidal Cells